whom ever would look at them as an acquisition will want all the information of this phase III trial and the efficacy of NOV-002. That in itself might turn a buyer away if indeed NOV-002 does absolutely nothing or worse, as it did in the leukemia study, increase the aggressiveness of the disease.
A lot of questions need to be answered before this sees any type of stabilization.
Market Data 
Markets 
AI
